In this Product Explainer, Infectious Diseases Physician and Microbiologist A/Prof Paul Griffin explains the role of oral anti-virals in the context of the current COVID-19 virology and available therapies.
In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).
In this Product Explainer, Rhinologist Prof Richard Harvey explains the role of olopatadine hydrochloride and mometasone furoate combination nasal spray in the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 6 years of age and older (5 mins).
In this Product Explainer, Rhinologist and Skull Base Surgeon A/Prof Raewyn Campbell explains the role of azelastine hydrochloride and fluticasone propionate nasal spray in the management of seasonal allergic rhinitis (5 mins).
In this Product Explainer, Dermatologist Dr Ryan De Cruz, explains the role of calcipotriol and betamethasone dipropionate foam spray for the topical treatment of psoriasis vulgaris in adults (6 mins).
In this Product Explainer, Professor of Obstetrics & Gynaecology, William Ledger explains the role of vaginal micronised progesterone, including the indication, safety profile, clinical trial background and guidelines for use for the treatment and management of threatened miscarriage (5 mins).
In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).
In this Product Explainer, Respiratory Physician Dr Adrian Barnett explains the role of fluticasone furoate, umeclidinium and vilanterol once-daily single inhaler triple therapy for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (5 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-PPTX-230007 Approved July 2023.
In this Product Explainer, Pharmacist Dr Jacinta Johnson explains the schedule 3 supply of triptans as Pharmacist Only Medicine, and presents several considerations when choosing the appropriate triptan for the acute management of migraine (6 mins).